Jakavi 5 mg – Ruxolitinib Oral Tablet

Jakavi 5 mg (Ruxolitinib) is a targeted oral therapy designed to inhibit JAK1 and JAK2 enzymes, key regulators in blood cell production and cytokine signaling. This pharmaceutical-grade tablet helps manage myeloproliferative disorders, blood cancers, and immune-related complications under physician supervision.

Uses of Jakavi 5 mg

Approved Uses

• Management of intermediate or high-risk myelofibrosis

• Treatment of polycythemia vera in patients intolerant or resistant to hydroxyurea

• Reduction of splenomegaly and disease-related symptoms

• Management of post-transplant immune complications

Off-Label / Investigational Uses

• Certain autoimmune or inflammatory conditions under research or physician guidance

• Investigational protocols for hematologic disorders

Mechanism of Action

Jakavi 5 mg works by inhibiting JAK1 and JAK2 enzymes, which regulate cytokine signaling and hematopoiesis. By modulating these pathways, it helps normalize blood cell production, reduce inflammation, and control abnormal immune responses.

Dosage & Administration

• Typical adult dose: 5 mg orally twice daily, or as prescribed

• Can be taken with or without food

• Dose adjustments may be required based on liver or kidney function

Common Side Effects

• Fatigue or headache

• Mild nausea or diarrhea

• Low blood counts (anemia, thrombocytopenia, neutropenia)

• Dizziness

Serious Side Effects

• Severe infections due to immune suppression

• Liver enzyme abnormalities

• Rare allergic reactions

• Blood clotting disorders

Drug Interactions

• CYP3A4 inhibitors or inducers may affect Ruxolitinib levels

• Monitor if combined with immunosuppressants or other hematologic drugs

• Consult a physician for all concurrent medications

Food & Lifestyle Interactions

• Can be taken with or without meals

• Avoid live vaccines due to immune suppression

• Regular monitoring of blood counts and liver function recommended

Monitoring & Tests

• Complete blood counts

• Liver and kidney function tests

• Monitoring for infections or adverse effects

Precautions & Warnings

• Use only under physician supervision

• Not recommended during pregnancy or breastfeeding without guidance

• Caution in patients with liver or kidney impairment

• Avoid abrupt discontinuation without medical advice